NEW YORK (GenomeWeb) – EntroGen said today that it has entered a new clinical collaboration with the University of Southern California Norris Comprehensive Cancer Center that will evaluate the clinical utility of EntroGen's liquid biopsy real-time PCR test in lung cancer patients.
According to EntroGen its ctEGFR test targets both EGFR TKI sensitizing mutations and acquired resistance mutations in as little as 1 ml of plasma. This is achieved via proprietary technology for ultra-sensitive detection of mutant variants on a background of normal circulating cell-free DNA.
With Norris, EntroGen is conducting a year-long study that will assess and monitor the levels of EGFR activating and resistance mutations in the blood of patients diagnosed with non-small cell lung cancer who are undergoing EGFR TKI therapy.
Other details of the collaboration agreement were not disclosed.